Last reviewed · How we verify

NCT04938440

Assessment of Updated Educational Materials for Instanyl®

Completed Last updated 1 August 2023
What this trial tests

trial in Pain in 536 participants. Completed in 6 February 2023.

Timeline
18 February 2022
Primary endpoint
6 February 2023
6 February 2023

Quick facts

Lead sponsorTakeda
StatusCompleted
Study typeOBSERVATIONAL
Enrollment536
Start date18 February 2022
Primary completion6 February 2023
Estimated completion6 February 2023
Sites1 location across United States

Conditions studied

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Pain or Cancer Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use. In this study, the doctors will complete two surveys: one three months before they receive the updated educational information, and one about six months after they receive this information. They will answer questions about their prescribing behavior plus their knowledge of Instanyl® including any risks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Takeda trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04938440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing